Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also ...
TORONTO, ON / ACCESSWIRE / June 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today the ...
Edesa Biotech Inc. (NASDAQ:EDSA) shares are trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19. The stock ...
La compañía, con sede en Cataluña, anuncia una renovación "progresiva" de sus firmas. Más información: Luis Monserrate, ...
TORONTO, ON / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that ...
Oral presentation at ERA Congress, the flagship European nephrology meeting; Company expects to present additional data ; TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, ...
TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research ...
Edesa Biotech, Inc. announced a successful private placement led by Velan Capital, raising approximately $15 million to advance its CXCL10 antibody program through fiscal 2026. The offering included ...
* EDESA BIOTECH - OBTAINED EXCLUSIVE RIGHTS THROUGHOUT WORLD TO CERTAIN KNOW-HOW, PATENTS & DATA RELATING TO MONOCLONAL ANTIBODIES TARGETING TLR4 & CXCL10 * EDESA BIOTECH INC - TERM OF LICENSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results